There are 3161 resources available
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03
1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Presenter: Santeri Pakola
Session: Poster session 03
1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03